CEO total compensation of approximately $14.7 million is within a reasonable range for a large-cap biotech CEO at a $27.8 billion company executing on multiple pivotal clinical programs, and the pay structure is heavily performance-oriented — the proxy discloses that 94% of CEO pay is 'at risk,' consisting of stock options and restricted stock units that only pay out if the stock price rises, plus an annual cash bonus tied to clearly defined clinical and operational goals. The 2025 bonus payout of 146% of target reflects genuine outperformance: the company executed ahead of schedule on multiple pivotal studies, initiated additional trials beyond target, and secured a major strategic financing — all verified corporate achievements. The prior Say-on-Pay vote received 98% support, the company maintains a robust clawback policy adopted in November 2023, and there are no pay-mix, dilution, or governance concerns that would warrant a negative vote.

PwC has audited RVMD since the fiscal year ended December 31, 2017 (approximately 9 years), well below the 25-year tenure threshold that would trigger a negative vote; non-audit fees of $110,000 represent only about 5.4% of audit fees of $2,036,000, comfortably below the 50% threshold; PwC is a Big 4 firm appropriate for a company of RVMD's $27.8 billion market cap; and no material financial restatements have been identified.